Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Nebraska Medical Center

My modifications based off the GRIFFIN trial (Voorhees et al., PMID 32325490) are as follows: If patients have high burden disease and no underlying neuropathy, I will start with twice-weekly bortezomib (days 1, 4, 8, 11) but will change the dexamethasone to 20 mg days 1, 4, 8, 11, and 15 using the ...

How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Nebraska Medical Center

My modifications based off the GRIFFIN trial (Voorhees et al., PMID 32325490) are as follows: If patients have high burden disease and no underlying neuropathy, I will start with twice-weekly bortezomib (days 1, 4, 8, 11) but will change the dexamethasone to 20 mg days 1, 4, 8, 11, and 15 using the ...

For those rare patients now out 5 years post GBM treatment and continuous Optune, is there a point one would stop Optune?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

I haven’t seen any data from Optune on these very long term survivors. They have released some subset data that patients who used the device 90% of the time or greater had a 29% chance of being alive at 5 years which is pretty remarkable. Certainly think there are diminishing returns beyond 5 years....

How do you approach the management of a patient with lumbar spinal metastasis with neurologic symptoms but without evidence of spinal cord compression?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arizona

From the brief description included, it appears that the lesion is at the level of the cauda equina, a group of nerves and nerve roots stemming from the distal end of the spinal cord, typically levels of L1-L5, and contains axons of nerves that give both motor and sensory innervation to the legs, bl...

What criteria do you use to decide whether to start anticonvulsants in patients with brain metastases?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

Patients with intact brain metastases in the absence of seizure activity should generally not be receiving prophylactic anticonvulsants based on 2019 guidelines from the Congress of Neurologic Surgeons subsequently endorsed by SNO and ASCO. The practice of prophylactic AEDs in the post-op setting is...

How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?

1
1 Answers

Mednet Member
Mednet Member
Neurology · MD Anderson Cancer Center

As soon as possible. The diagnostic yield of biopsy or LP can diminish very quickly after steroid initiation. Holding steroids for 7-10 days if possible is one common strategy to try to mitigate this. If steroids are unavoidable, or if tapering/holding them is not feasible, additional strategies to ...

How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?

1
1 Answers

Mednet Member
Mednet Member
Neurology · MD Anderson Cancer Center

As soon as possible. The diagnostic yield of biopsy or LP can diminish very quickly after steroid initiation. Holding steroids for 7-10 days if possible is one common strategy to try to mitigate this. If steroids are unavoidable, or if tapering/holding them is not feasible, additional strategies to ...

When is the best time to try targeted therapy in adult-type diffuse non-IDH glioma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Sitti Sitti and pitirrangoon, MD

Has this practice changed since posted?

Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center

Data from Tsuji et al., PMID 38287788 and Naidoo et al., JCO 2022 suggest that patients with EGFRm NSCLC do not benefit from durvalumab after concurrent CRT. While the majority of patients studied had tumors driven by classic sensitizing mutations, atypicals were included in the series from Japan. B...

For patients with seminoma testicular cancer who are Stage II (positive retroperitoneal lymph nodes), what factors do you consider when choosing between radiation versus chemotherapy?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Testicular Cancer Commons

I usually look at the size of the retroperitoneal adenopathy, the age of the patient and the anticipated tolerance of chemotherapy. Disease > 3cm in the retroperitoneum is most often treated with chemotherapy. Less than 3 cm, it becomes a clinical judgement. Older patients probably have lower risk o...